MesomiR 1: A Phase I Study of Intravenously Administered Epidermal Growth Factor Receptor -Targeted, EnGeneIC Delivery Vehicle (EDV)-Packaged, miR-16 Mimic (TargomiRs) for Patients With Malignant Pleural Mesothelioma (MPM) and Advanced Non-Small Cell Lung Cancer (NSCLC) Failing on Std Therapy

Trial Profile

MesomiR 1: A Phase I Study of Intravenously Administered Epidermal Growth Factor Receptor -Targeted, EnGeneIC Delivery Vehicle (EDV)-Packaged, miR-16 Mimic (TargomiRs) for Patients With Malignant Pleural Mesothelioma (MPM) and Advanced Non-Small Cell Lung Cancer (NSCLC) Failing on Std Therapy

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs MicroRNA encapsulated nanocells EnGeneIC (Primary)
  • Indications Mesothelioma; Non-small cell lung cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms MesomiR-1
  • Most Recent Events

    • 05 Sep 2017 Results published in an EnGeneIC Media Release.
    • 05 Sep 2017 According to an EnGeneIC media release, data were published in journal, The Lancet Oncology.
    • 01 Sep 2017 Results published in the Lancet Oncology Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top